Coridea is a medical device incubator driven by an innovative, translational health care approach. The firm is developing unexpected device solutions that change the lives of cardiac, pulmonary and renal patients who have failed drug treatment.
Dr. Brian Dixon serves as Venture Partner at Elm Street Ventures. He also serves as the Chief Executive Officer of BioRelix, Inc. Prior to joining BioRelix in October 2007, Dr. Dixon served as Vice President with Bayer HealthCare in West Haven Connecticut. In that position, he led a multi-disciplinary organization of up to 130 employees that delivered state-of-the-art expertise in oncology biomarker discovery, new lead discovery, research drug formulation, pharmacokinetics and drug metabolism to Bayer's global R&D business. In addition, he held leadership roles in R&D licensing initiatives, strategic alliances and cross divisional collaborations in translational medicine. From 1998 to 2001, Dr. Dixon directed Bayer drug discovery efforts in both the Osteoporosis and Oncology therapeutic areas. He serves as a Director of BioRelix, Inc. Dr. Dixon was an undergraduate at the University of Michigan. He received his Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology and completed post-doctoral training at Harvard University.
He is a serial entrepreneur and angel investor in innovation. Besides being responsible for the overall administration of Translated, Marco is pursuing research in machine learning models for integrating machine translation in a human translation workflow. He invests in growth-stage technology ventures through Pi Campus.